Elan and Wyeth to take Alzheimer's drug to phase III

July 2007
PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p6
Market Research Report
The article reports on the plan of Elan Corp. and Wyeth Pharmaceuticals to initiate a phase III clinical program for bapineuzumab, a humanized monoclonal antibody which is used to treat patients with mild to moderate Alzheimer's disease. According to the author, the move was based on a scheduled interim look at data from an ongoing phase II study, which remains blinded. The trial is expected to begin in the second half of 2007.


Related Articles

  • Elan/Wyeth unveil significant findings from phase IIa trial of AN-1792.  // PharmaWatch: CNS;September 2004, Vol. 3 Issue 9, p7 

    Reports on the findings of Elan Corp. and Wyeth Pharmaceuticals Inc.'s phase IIa clinical trial of an investigational Alzheimer's disease treatment drug, AN-1792. Beta amyloid immunotherapy approach; Use of an immunologic approach to clear beta amyloid from the brain; Evidence of beta amyloid...

  • J&J-Pfizer's Alzheimer's Drug Crashes, Burns in Phase III. Sheridan, Cormac // BioWorld International;8/8/2012, Vol. 17 Issue 32, p1 

    The article reports on the failure of Pfizer Inc. and Johnson and Johnson's bapineuzumab to pass the Phase III trial in Alzheimer's disease. It notes that the antibody, which is discovered and developed by Elan Corp. PLC, has failed to meet the co-primary cognitive and functional performance...

  • Alzheimer's Drug Boosts Elan's Stock.  // Bioworld Week;5/28/2007, Vol. 15 Issue 22, p2 

    The article reports that the plan of Elan Corp. PLC and Wyeth Pharmaceuticals to begin Phase III testing of their immunotherapeutic candidate bapineuzumab for mild to moderate Alzheimer's disease in the second half of 2007 has boosted trading values of Elan's stocks. The reports says that Elan's...

  • Myriad stumbles, Wyeth closes on Alzheimer's. Osborne, Randy // Nature Biotechnology;Aug2008, Vol. 26 Issue 8, p841 

    This article discusses efforts to develop medications for the treatment of Alzheimer's disease. Clinical trials of the human monoclonal antibody bapinezumab, under development by Wyeth, and the γ- and Β-secretase modulator Flurizan (R-flurbiprofin), under development by Myriad are...

  • Alzheimer's Disease Update.  // PharmaWatch: CNS;Aug2008, Vol. 7 Issue 8, p5 

    The article offers news briefs related to the pharmaceutical industry. Elan Corp. PLC and Wyeth have announced the positive preliminary findings of the Phase II study of bapineuzumab in patients with Alzheimer's disease. Myriad Genetics Inc. has also reported the results of the ActEarli-AD trial...

  • Call for Elan to publish Alzheimer's trial details. Bishop, Glenda M.; Robinson, Stephen R.; Smith, Mark A.; Perry, George; Atwood, Craig S. // Nature;4/18/2002, Vol. 416 Issue 6882, p677 

    Focuses on the request of the authors to Elan Pharmaceuticals to publish the details of the trial of the treatment of Alzheimer's disease. Release of Elan of details of their medical condition; Withdrawal of Elan of AN-1792 vaccine from human trials; Lack of obligation of Elan to report the...

  • Elan-Wyeth Alzheimer's Trial Suspended Due to Skin Lesion. Hollingsworth, Catherine // BioWorld International;4/23/2008, Vol. 13 Issue 17, p6 

    The article discusses the suspension of the Phase II trial study of the ACC-011 compound for Alzheimer's disease in 2008. The compound is being developed by Elan Corp. plc and Wyeth Pharmaceuticals. An announcement regarding the suspension was posted on April 17 on the Web site,...

  • Elan and Wyeth start Phase III Alzheimer's trial for bapineuzumab.  // PharmaWatch: Biotechnology;Feb2008, Vol. 7 Issue 2, p6 

    The article reports on the Phase III clinical program for bapineuzumab in patients with mild to moderate Alzheimer's disease initiated by Elan Corp. PLC and Wyeth Pharmaceuticals in the U.S. The trial is intended to provide safety and efficacy data to support the filing and approval. It includes...

  • Elan-Wyeth Alzheimer Trial Suspended.  // Bioworld Week;4/28/2008, Vol. 16 Issue 17, p2 

    The article reports on the suspension of Phase II trial of ACC-011 compound for Alzheimer's disease due to a skin lesion seen in a single patient. It states that the compound was developed by Elan Corp. Plc and Wyeth Pharmaceuticals, and both companies are sorting out the origin and cause of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics